SG11201509194SA - Radiomitigating pharmaceutical formulations - Google Patents
Radiomitigating pharmaceutical formulationsInfo
- Publication number
- SG11201509194SA SG11201509194SA SG11201509194SA SG11201509194SA SG11201509194SA SG 11201509194S A SG11201509194S A SG 11201509194SA SG 11201509194S A SG11201509194S A SG 11201509194SA SG 11201509194S A SG11201509194S A SG 11201509194SA SG 11201509194S A SG11201509194S A SG 11201509194SA
- Authority
- SG
- Singapore
- Prior art keywords
- radiomitigating
- pharmaceutical formulations
- formulations
- pharmaceutical
- radiomitigating pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361820447P | 2013-05-07 | 2013-05-07 | |
| PCT/US2014/037110 WO2014182789A2 (en) | 2013-05-07 | 2014-05-07 | Radiomitigating pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509194SA true SG11201509194SA (en) | 2015-12-30 |
Family
ID=51867859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509194SA SG11201509194SA (en) | 2013-05-07 | 2014-05-07 | Radiomitigating pharmaceutical formulations |
Country Status (11)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130203722A1 (en) | 2006-09-26 | 2013-08-08 | Rhonda R. Voskuhl | Estriol therapy for autoimmune and neurodegenerative disease and disorders |
| CA2911902A1 (en) * | 2013-05-07 | 2014-11-13 | The Regents Of The University Of California | Radiomitigating pharmaceutical formulations |
| WO2017156222A1 (en) * | 2016-03-09 | 2017-09-14 | The Regents Of The University Of California | Radiomitigating compounds, compositions and methods related thereto |
| US20180104233A1 (en) * | 2016-10-16 | 2018-04-19 | BCN Biosciences L.L.C. | Methods of treatment and pharmaceutical compositions using bcn057 or bcn512 |
| US20190046524A1 (en) * | 2017-08-08 | 2019-02-14 | BCN Biosciences L.L.C. | Methods of treating radiation induced gastrointestinal syndrome (rigs) and related disease states using compound 512 |
| WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4159331A (en) * | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| EP1056732B1 (en) | 1997-10-27 | 2006-01-11 | Agouron Pharmaceuticals, Inc. | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
| US6407120B1 (en) | 1999-02-18 | 2002-06-18 | Pfizer Inc. | Neuropeptide Y antagonists |
| IT1313594B1 (it) * | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Bisplatino complessi attivi per via orale. |
| US7223751B2 (en) * | 2001-04-26 | 2007-05-29 | Kolon Ind. Inc. | Sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same |
| EP1689706B1 (en) * | 2003-11-14 | 2017-01-11 | Temple University - Of The Commonwealth System of Higher Education | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders |
| JP2005232101A (ja) * | 2004-02-20 | 2005-09-02 | Rikogaku Shinkokai | セレコキシブアミノアルキル誘導体 |
| US7345043B2 (en) | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| MY140912A (en) * | 2004-07-26 | 2010-01-29 | Du Pont | Mixtures of anthranilamide invertebrate pest control agents |
| US7615570B2 (en) * | 2004-12-13 | 2009-11-10 | Abbott Laboratories | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| WO2007029078A2 (en) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Succinimide and glutarimide derivatives as adrenergic receptor antagonists |
| MX2008015696A (es) | 2006-06-09 | 2009-02-10 | Icos Corp | Acidos fenil aceticos sustituidos como antagonistas de dp-2. |
| CN101516361A (zh) | 2006-09-28 | 2009-08-26 | 亚瑞特医疗公司 | 可溶性环氧化物水解酶抑制剂 |
| JP2011526925A (ja) | 2008-07-01 | 2011-10-20 | ザカロン ファーマシューティカルズ，インク． | ヘパラン硫酸阻害剤 |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| EP2411529A4 (en) * | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | MODULATORS OF BIOSYNTHESIS OF N-BOUND GLYCANS |
| US8546397B2 (en) * | 2010-12-20 | 2013-10-01 | The Ohio State University Research Foundation | DNA methylation inhibitors |
| US9217000B2 (en) * | 2011-02-18 | 2015-12-22 | Univerisyt of Pittsburgh—of the Commonwealth System of Higher Education | Targeted nitroxide agents |
| CA2911902A1 (en) * | 2013-05-07 | 2014-11-13 | The Regents Of The University Of California | Radiomitigating pharmaceutical formulations |
-
2014
- 2014-05-07 CA CA2911902A patent/CA2911902A1/en not_active Abandoned
- 2014-05-07 US US14/889,719 patent/US9783515B2/en active Active
- 2014-05-07 EP EP14794084.5A patent/EP2994457B1/en active Active
- 2014-05-07 AU AU2014262764A patent/AU2014262764B2/en active Active
- 2014-05-07 SG SG11201509194SA patent/SG11201509194SA/en unknown
- 2014-05-07 WO PCT/US2014/037110 patent/WO2014182789A2/en active Application Filing
- 2014-05-07 JP JP2016513039A patent/JP2016523830A/ja active Pending
- 2014-05-07 KR KR1020157034769A patent/KR20160005356A/ko not_active Ceased
- 2014-05-07 ES ES14794084T patent/ES2860949T3/es active Active
- 2014-05-07 CN CN201480038705.0A patent/CN105579439B/zh active Active
-
2015
- 2015-11-08 IL IL242493A patent/IL242493B/en active IP Right Grant
-
2016
- 2016-04-08 US US15/094,192 patent/US9840483B2/en active Active
-
2017
- 2017-11-14 US US15/812,321 patent/US20180162827A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2860949T3 (es) | 2021-10-05 |
| WO2014182789A2 (en) | 2014-11-13 |
| JP2016523830A (ja) | 2016-08-12 |
| CN105579439A (zh) | 2016-05-11 |
| IL242493A0 (en) | 2016-02-01 |
| US9840483B2 (en) | 2017-12-12 |
| CN105579439B (zh) | 2018-10-19 |
| EP2994457B1 (en) | 2021-01-06 |
| KR20160005356A (ko) | 2016-01-14 |
| AU2014262764A1 (en) | 2015-12-17 |
| EP2994457A2 (en) | 2016-03-16 |
| IL242493B (en) | 2020-08-31 |
| AU2014262764B2 (en) | 2018-11-15 |
| WO2014182789A3 (en) | 2014-12-11 |
| US20160221976A1 (en) | 2016-08-04 |
| US20160090369A1 (en) | 2016-03-31 |
| US9783515B2 (en) | 2017-10-10 |
| CA2911902A1 (en) | 2014-11-13 |
| EP2994457A4 (en) | 2016-09-28 |
| US20180162827A1 (en) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288961A (en) | Pharmaceutical preparations | |
| SMT201900684T1 (it) | Composizione farmaceutica combinata | |
| GB201319791D0 (en) | Formulations | |
| PL2943181T3 (pl) | Kompozycje farmaceutyczne | |
| EP2991639A4 (en) | PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE | |
| ZA201408333B (en) | Pharmaceutical compositions | |
| GB201319792D0 (en) | Formulations | |
| SG11201509194SA (en) | Radiomitigating pharmaceutical formulations | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| GB201318686D0 (en) | Pharmaceutical preparations | |
| ZA201600027B (en) | Pharmaceutical preparation | |
| GB201301721D0 (en) | Pharmaceutical Preparations | |
| HUP1300496A2 (hu) | Stabil kombinációs gyógyszerkészítmény | |
| IL244365A0 (en) | pharmaceutical preparation | |
| SG11201509114TA (en) | Pharmaceutical compositions | |
| GB201304699D0 (en) | Pharmaceutical compositions | |
| IL244316A0 (en) | A new composition of a drug | |
| ZA201506465B (en) | Pharmaceutical preparation | |
| GB201321497D0 (en) | Pharmaceutical compositions | |
| GB201312851D0 (en) | Pharmaceutical compositions | |
| GB201316662D0 (en) | Pharmaceutical Combination | |
| GB201310496D0 (en) | Pharmaceutical combinations | |
| GB201319024D0 (en) | Reduced viscosty protein pharmaceutical formulations | |
| GB201301723D0 (en) | Pharmaceutical combinations |